NO20063801L - Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse - Google Patents

Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse

Info

Publication number
NO20063801L
NO20063801L NO20063801A NO20063801A NO20063801L NO 20063801 L NO20063801 L NO 20063801L NO 20063801 A NO20063801 A NO 20063801A NO 20063801 A NO20063801 A NO 20063801A NO 20063801 L NO20063801 L NO 20063801L
Authority
NO
Norway
Prior art keywords
agonists
vpac2
receptor
pacap
pituitary
Prior art date
Application number
NO20063801A
Other languages
English (en)
Norwegian (no)
Inventor
Kevin Clairmont
Kevin J Lumb
Thomas Buckholz
Arthur I Salhanick
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20063801L publication Critical patent/NO20063801L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
NO20063801A 2004-01-27 2006-08-25 Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse NO20063801L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53955004P 2004-01-27 2004-01-27
US56649904P 2004-04-29 2004-04-29
PCT/US2005/002609 WO2005072385A2 (en) 2004-01-27 2005-01-27 Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use

Publications (1)

Publication Number Publication Date
NO20063801L true NO20063801L (no) 2006-10-26

Family

ID=34830483

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063801A NO20063801L (no) 2004-01-27 2006-08-25 Hypofyse-adenylat-syklaseaktiverende-peptid-(PACAP)-reseptor (VPAC2)-agonister og deres farmakologiske anvendelse

Country Status (13)

Country Link
US (1) US20090143283A1 (enExample)
EP (1) EP1713493A4 (enExample)
JP (1) JP2007519739A (enExample)
KR (1) KR20070009554A (enExample)
AU (1) AU2005208911A1 (enExample)
BR (1) BRPI0507177A (enExample)
CA (1) CA2554475A1 (enExample)
EC (1) ECSP066793A (enExample)
IL (1) IL176705A0 (enExample)
MA (1) MA28335A1 (enExample)
NO (1) NO20063801L (enExample)
RU (1) RU2006130691A (enExample)
WO (1) WO2005072385A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575101A1 (en) * 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
EP1896048A4 (en) * 2005-05-06 2010-11-03 Bayer Pharmaceuticals Corp PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
KR101057284B1 (ko) 2005-10-26 2011-08-16 일라이 릴리 앤드 캄파니 선택적 ｖｐａｃ２ 수용체 펩티드 작동제
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
CA2983030A1 (en) 2015-04-16 2016-10-20 Alder Biopharmaceuticals, Inc. Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
SG10202109691UA (en) 2016-04-15 2021-10-28 Alder Biopharmaceuticals Inc Anti-pacap antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
DE60039111D1 (de) * 1999-09-28 2008-07-17 Bayer Corp Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung
US20050009739A1 (en) * 2002-02-14 2005-01-13 Wei Wang Formulation strategies in stabilizing peptides in organic solvents and in dried states
US7378494B2 (en) * 2002-07-12 2008-05-27 Bayer Healthcare Ag Pituitary adenylate cyclase activating peptide (PACAP) receptor (VPAC2) agonist peptide

Also Published As

Publication number Publication date
MA28335A1 (fr) 2006-12-01
EP1713493A2 (en) 2006-10-25
JP2007519739A (ja) 2007-07-19
KR20070009554A (ko) 2007-01-18
WO2005072385A2 (en) 2005-08-11
AU2005208911A1 (en) 2005-08-11
ECSP066793A (enExample) 2006-11-16
IL176705A0 (en) 2006-10-31
CA2554475A1 (en) 2005-08-11
BRPI0507177A (pt) 2007-06-26
EP1713493A4 (en) 2009-06-24
WO2005072385A3 (en) 2006-06-08
RU2006130691A (ru) 2008-03-10
US20090143283A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
KR100518046B1 (ko) Ｇｌｐ-1을 사용한 급성 관상동맥 증후군의 치료
UY27893A1 (es) Agonistas del receptor (vpac2) del peptido activante de la adenilatociclasa hipofisaria (pacap) y sus metodos de uso farmacologicos
CN103665148B (zh) 一种可口服给药的降糖多肽及其制法和用途
ES2549955T3 (es) Prevención de hipoglucemia en pacientes con diabetes mellitus de tipo 2
Lieblich et al. 4S-Hydroxylation of insulin at ProB28 accelerates hexamer dissociation and delays fibrillation
CN104144704B (zh) Glp‑1受体激动剂肽胃泌素缀合物
WO2006121860A3 (en) Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
NO20055129L (no) Fenylsubstituerte karboksylsyrer
US20140142023A1 (en) Pharmaceutical Composition for Treating A Metabolic Syndrome
WO2007140284A3 (en) N-terminally modified glp-1 receptor modulators
BRPI0418702A (pt) composição para a liberação sustentada de polipetìdeo biologicamente ativo, método para tratar um paciente sofrendo de diabetes tipo 2, processo para preparar uma composição para a liberação sustentada de um polipeptìdeo, composição para a liberação sustentada de um agente biologicamente ativo, processo para preparar uma composição para a liberação sustentada de exendina-4, composição injetável, kit para produzir uma composição injetável, composição farmaceuticamente aceitável para a liberação sustentada de um polipeptìdeo biologicamente ativo e método para tratar um paciente sofrendo de diabetes mellitus
ATE482717T1 (de) Peptid yy (pyy) zur behandlung von glukose stoffwechselkrankheiten
EA200900896A1 (ru) Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений
NO20054769L (no) Substituerte fenylalkansyrer
NO20054534L (no) Leveringssystem for legemiddel og celleterapi
NO20054958L (no) Substitulerte aminokarboksylsyrer
WO2006014287A8 (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
WO2007082264A3 (en) Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
AU2016324119B2 (en) Long-acting adrenomedullin derivative
WO2019008033A1 (en) METHODS AND MEDICAL USES RELATING TO THE TREATMENT OF HYPOGLYCEMIA
Yoo et al. Formulary forum: Exenatide: A new option for the treatment of type 2 diabetes
EA200600402A1 (ru) Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови
WO2011128782A3 (en) Compositions and methods for treating type ii diabetes and related disorders
Mest Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement
BRPI0507177A (pt) agonistas (vpac2) do receptor peptìdico de ativação de adenilato ciclase pituitários (pacap) e seus métodos farmacológicos de uso

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application